of Inotek Pharmaceuticals Corporation (“ Inotek ”) and Rocket Pharmaceuticals, Ltd. (“ Rocket ”), pursuant to the terms of an Agreement and Plan of Merger and Reorganization, dated September 12, 2017, by and between Inotek, Rocket and Rome Merger Sub, a wholly owned subsidiary of Inotek (the “ Merger Agreement ”). The following slides were used in connection with a conference call held by Inotek and Rocket on September 13, 2017: |